Emcure Pharmaceuticals Ltd (BOM:544210)

Q3 2026 Emcure Pharmaceuticals Ltd Earnings Call Transcript

Feb 4, 2026 / 10:30 AM GMT

Release Date Price: ₹1535.2 (+1.96%)

Transcript

Key Points

Positve

Emcure Pharmaceuticals Ltd (BOM:544210) reported a 20.4% year-on-year revenue growth for Q3 FY26, demonstrating strong business performance.
The company achieved a 48% growth in profit after tax, reflecting robust financial health.
The domestic business recorded a 15% year-on-year growth, driven by strong performance across key therapies such as cardio, CNS, and oncology.
International markets showed a 24.5% growth, with Europe experiencing a significant 29.6% increase, led by the ramp-up of new products.
Emcure Pharmaceuticals Ltd (BOM:544210) entered an exclusive partnership with Novo Nordisk, launching an innovative drug in the semaglutide category, enhancing its product portfolio and market position.

Negative

Gross margins declined slightly to 59.3% from 60.1% due to the unlicensing of the Sanofi OAD portfolio and changes in business mix.
The company faced a one-time exceptional expense of 38 crores related to labor code changes, impacting financial results.
There is potential for increased competition in the semaglutide market, which could affect future market share and profitability.
The company's net debt increased to 1,200 crores, primarily due to the payout for Juventus minority stake.
Despite strong growth, the gross margin pressure from the faster-growing international business compared to the domestic business could continue to impact overall profitability.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

EMCU.NS - Emcure Pharmaceuticals Ltd
Q3 2026 Emcure Pharmaceuticals Ltd Earnings Call
Feb 04, 2026 / 10:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to Mcure Pharmaceuticals Limited Q3F526 earnings conference call.

As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing then 0 on your touchstone phone. Please note that this conference is being recorded.

I now hand the conference over to Mr. Push Nahar, EVP, Corporate Strategy and Development.

Thank you and over to you, Mr. Nahar.

--------------------------------------------------------------------------------
Unidentified_2 [2]
------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.